

July 23, 2008

## Glaxo Braces for Probes, Hires FDA Ex-Litigator

**Troy Led Agency Effort  
Backing Drug Makers  
In Fighting Lawsuits**

By ALICIA MUNDY  
*July 23, 2008; Page B7*

**GlaxoSmithKline PLC**, which is facing various federal and congressional investigations, has hired Daniel Troy, a former chief counsel for the U.S. Food and Drug Administration, as its new general counsel.

Mr. Troy, currently a partner at the Washington law firm Sidley Austin LLP, represents pharmaceutical companies and trade associations that deal with the FDA. Glaxo said he was appointed the U.K drug giant's senior vice president and general counsel, effective Sept. 2.

"Dan shares our vision that it is critical in today's health-care environment that we deliver differentiated products of real value," said Andrew Witty, Glaxo's chief executive officer. "His wealth of experience in the regulatory legislative area will be of enormous benefit to us, and ultimately to patients," Mr. Witty added.

Mr. Troy managed FDA agency litigation from 2001 to 2004. Under Mr. Troy, the agency began filing amicus briefs opposing lawsuits against drug and medical-device makers, saying that having met the FDA's approval and labeling standards, manufacturers should be protected from state-based suits for damages.

Prior to his appointment to the FDA, Mr. Troy fought the agency on behalf of the right to use medical-journal articles to suggest off-label uses for drugs and medical devices.

Representing the **Washington Legal Foundation**, an industry-supported business think tank, Mr. Troy argued for the protection of commercial speech and won that case in District Court in Washington in 1998. He was also part of the winning team representing Brown & Williamson in a suit against the FDA regarding tobacco advertising.

**Write to** Alicia Mundy at [alicia.mundy@wsj.com](mailto:alicia.mundy@wsj.com)<sup>1</sup>